Eli Lilly

What Eli Lilly does

Eli Lilly and Company is a 150-year-old global pharmaceutical company that develops, manufactures, and markets branded human medicines across diabetes, obesity, oncology, neuroscience, immunology, and rare diseases. The company is built on a deep R&D base of approximately 12,524 scientific staff (about 25% of its 50,762-person workforce) and roughly $13.3 billion in annual R&D spend, and is supported by manufacturing operations in 10 countries including a $21 billion Indiana facility dedicated to API and oral GLP-1 production. Its most strategically significant franchises are Mounjaro and Zepbound (tirzepatide, a GIP/GLP-1 dual agonist) and the newly approved Foundayo (orforglipron), the first oral small-molecule GLP-1, which together anchor its metabolic-disease franchise; its portfolio also includes Verzenio and Jaypirca in oncology, AJX-101 in small-molecule immunotherapy, and a growing cell-and-gene-therapy platform acquired through Orna and Sigilon.

The business model is a traditional branded-pharma model with three notable modernizations. First, the company has built LillyDirect, a direct-to-consumer portal integrating teleprescribing and dispensing, with partnerships spanning Amazon Pharmacy, Walmart (4,600+ stores), and telehealth providers such as HealthTap, Sesame, WW, Cove, and Ro — shortening the path from prescription to therapy and capturing first-party data. Second, the company has reshaped GLP-1 access economics with the Medicare GLP-1 Bridge program, which prices tirzepatide at $50/month for roughly 20 million eligible Medicare beneficiaries. Third, the company has built a digital R&D infrastructure around a dedicated NVIDIA drug-discovery supercomputer and the BioNeMo Agent Toolkit, with AI-co-designed antibody programs (e.g., ABS-201 with Absci) and AI-driven clinical-trial design.

In 2025 Eli Lilly reported revenue of $65.179B (+45% YoY), with first-quarter 2026 revenue of $19.8B and full-year 2026 management guidance of $82-85B. The customer base is highly distributed — roughly 71 million patients treated across approximately 90 countries, served through individual prescribers, retail pharmacies, 340B hospitals, telehealth platforms, and DTC channels. The portfolio is regulated under multiple FDA Breakthrough Therapy and Priority Review Voucher designations, and the company holds 10 Prix Galien Awards, more than any other firm. The dominant revenue risk is product concentration: tirzepatide is forecast to exceed $70B by 2032, and the company's growth trajectory is therefore highly dependent on continued GLP-1 pricing power, supply expansion, and successful cross-portfolio diversification through the $25B+ of M&A executed in 2026.

Name

Eli Lilly

Legal name

Eli Lilly and Company

Website

https://www.lilly.com

Company type

Public

Founded year

1876

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Eli Lilly and Company is a 150-year-old global pharmaceutical company developing branded medicines across diabetes, obesity, oncology, neuroscience, and immunology, anchored by its GIP/GLP-1 franchise (Mounjaro, Zepbound, and oral Foundayo) and supported by $13.3 billion in R&D and manufacturing in ten countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

Keywords

• Prescription pharmaceuticals
• Diabetes medications
• Oncology therapeutics
• Biopharmaceutical medicines
• Rare disease treatments

Headquarters

HQ city

Indianapolis

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Pharmaceutical product sales: Primary revenue stream from sales of proprietary branded medicines (Mounjaro, Zepbound, Trulicity, Humalog, Verzenio, Taltz, Cyramza, etc.) across approximately 90 countries; 2025 reported revenue of $65,179M.
2. Direct-to-consumer pharmacy fulfillment (LillyDirect): Self-pay and insurance-based sales channel via LillyDirect, providing home delivery or retail pickup of Lilly medicines through third-party pharmacy providers (Prescryptive, Amazon Pharmacy, Fuze Health, Gifthealth, Walmart).
3. Out-licensing and royalty income: Royalties and milestones from collaboration partners (e.g., $9.2M private placement in ProQR, milestone/royalty arrangements in Abbisko, BioArctic, Oryn) and licensed product agreements.
4. Capital markets financing (debt): Senior notes issuances used to fund R&D and M&A pipeline investments (e.g., $6.5 billion notes offering in February 2024).

Pricing tiers

Go-to-market motion6 records

Distribution channels10 records

Marketing channels9 records

Core offering

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and sells proprietary prescription medicines across diabetes, obesity, oncology, neuroscience, immunology, and rare diseases. Its flagship franchise is the tirzepatide-based incretin portfolio (Mounjaro, Zepbound, Foundayo) for type 2 diabetes, chronic weight management, and obstructive sleep apnea, complemented by oncology, immunology, Alzheimer's, migraine, and insulin products marketed in approximately 90 countries. The company also operates LillyDirect, a direct-to-consumer digital pharmacy and telehealth platform providing home delivery of authentic Lilly medicines.

Product overview

Eli Lilly operates as a platform-plus-modules pharmaceutical portfolio anchored by its flagship metabolic-disease franchise (Mounjaro, Zepbound, Trulicity, Foundayo) and a broad therapeutic portfolio spanning diabetes, oncology, neuroscience, immunology, and rare disease. Around this core, Lilly has layered a direct-to-consumer digital platform (LillyDirect) that integrates telehealth providers, pharmacy fulfillment partners (Amazon Pharmacy, Walmart Pharmacy, Gifthealth, Fuze Health, Prescryptive), and wearable integrations (Oura), enabling patients to access select Lilly therapies with home delivery. The portfolio also includes acquired biotech brands (Loxo Oncology, Akouos, Morphic, Verve Therapeutics, Point Biopharma) extending Lilly into precision oncology, gene therapy, gene editing, and radioligand therapy, while AI-driven drug discovery (in partnership with NVIDIA) underpins the R&D engine behind both core and acquired products.

Differentiator

Problem solved

Functional benefit

Brands

• LillyDirect: Direct-to-consumer pharmacy platform providing authentic Lilly medicines, free home delivery or retail pickup, transparent pricing, savings support, and prior authorization coordination.
• Lilly Catalyze 360
• Loxo at Lilly
• Mounjaro
• Zepbound
• Foundayo
• Trulicity
• Humalog
• Humulin
• Basaglar
• Rezvoglar
• Lyumjev
• Emgality
• Ebglyss
• Kisunla
• Jaypirca
• Inluriyo
• Omvoh
• Tanstrive

Products and services

• Mounjaro
• Zepbound
• Trulicity
• Foundayo (orforglipron)
• Humalog
• Humulin
• Basaglar
• Rezvoglar
• Lyumjev
• Emgality
• Ebglyss (lebrikizumab)
• Kisunla (donanemab)
• Jaypirca (pirtobrutinib)
• Omvoh (mirikizumab)
• Inluriyo (imlunestrant)
• Tanstrive (selpercatinib)
• Verzenio (abemaciclib)
• Cyramza (ramucirumab)
• Prozac (fluoxetine)
• Cymbalta (duloxetine)
• Zyprexa (olanzapine)
• LillyDirect
• Medicare GLP-1 Bridge Program

Quantifiable outcome

• Zepbound demonstrates average weight loss of up to 20.9% in clinical trials
• +9 more outcomes

Named customers1 record

Segments10 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability3 records

Feature9 records

Partnerships

35 partnerships are on record, tiered flagship and core.

• Kelonia TherapeuticsflagshipStrategic or Co-development Partner · 25 June 2026Acquisition for up to $7 billion as one of three Eli Lilly deals among the top ten largest U.S. venture-backed startup acquisitions in 2026. Part of Lilly's $25B+ 2026 M&A commitment to expand in cell therapy and genetic medicine.
• RAISE US (Gina Raimondo, Eric Holcomb)coreGTM or Marketing Partner · 25 June 2026Bipartisan nonprofit coalition with over $500 million in funding to help American workers adapt to AI-driven job displacement. Anchor partners include Amazon, Microsoft, Anthropic, OpenAI, Bank of America, UPS, General Motors, Eli Lilly, Mastercard, AMD, Cisco, and IBM. Pilots launching in Arkansas, Maryland, Utah, and Connecticut with goal of raising $1 billion.
• Abbisko TherapeuticsflagshipStrategic or Co-development Partner · 24 June 2026Strategic research collaboration and license agreement under which Abbisko will lead discovery and early-stage development activities for novel drug programs targeting diseases selected by Lilly. Financial terms include an upfront payment to Abbisko plus up to $1.9 billion in development, regulatory, and commercial milestones, plus tiered royalties on net sales. Builds on a prior 2022 partnership worth up to $258 million focused on small-molecule therapeutics.
• Oura Health (Oura Ring)coreTechnology or Integration · 23 June 2026Partnership between Oura wearable and LillyDirect (Eli Lilly's direct-to-consumer telehealth platform) to help patients on GLP-1 weight loss medications track health changes through Oura's wearable devices. Integrates Oura's tracking capabilities with Eli Lilly's prescription platform.
• Sangamo TherapeuticsflagshipStrategic or Co-development Partner · 23 June 2026Asset sale agreement (alongside Astellas) following Sangamo's Chapter 11 bankruptcy filing. Lilly will acquire Sangamo's capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and prion disease program (ST-506); Astellas will acquire the Fabry disease program isaralgagene civaparvovec. Lilly offered $50 million for technology platforms in stalking horse bid.
• Mediar TherapeuticscoreStrategic or Co-development Partner · 23 June 2026Global partnership covering MTX-463, a novel anti-fibrotic program for idiopathic pulmonary fibrosis. Mediar is advancing three novel anti-fibrotic programs in clinical development including MTX-439 for fibrosis associated with chronic kidney disease.
• Oryn TherapeuticscoreStrategic or Co-development Partner · 23 June 2026Catalyze agreement with Lilly ExploR&D to access scientific capabilities for accelerating Oryn's Orynotide™ macrocyclic peptide platform development for treating inflammatory, autoimmune, and fibro-inflammatory diseases.
• BioArctic ABflagshipStrategic or Co-development Partner · 22 June 2026Research and collaboration agreement combining BioArctic's proprietary BrainTransporter blood-brain barrier delivery technology with an undisclosed Lilly drug candidate targeting neurodegeneration. BioArctic will receive $30 million upfront and up to $770 million in milestone payments plus tiered mid-single-digit royalties on future global product sales. Lilly assumes full responsibility for global development and commercialization. This is BioArctic's fourth BrainTransporter collaboration, following deals with Eisai, Bristol Myers Squibb, and Novartis.
• 4E TherapeuticscoreStrategic or Co-development Partner · 22 June 2026Acquisition of Austin-based neuroscience company developing orally available MNK inhibitors for chronic pain treatment targeting the MNK-eIF4E signaling pathway. Undisclosed financial terms.
• Centessa PharmaceuticalsflagshipStrategic or Co-development Partner · 31 March 2026Definitive agreement to acquire Centessa for approximately $7.8 billion ($38.00 per share plus up to $9.00 per share contingent value right). Expands Lilly's neuroscience portfolio into sleep medicine, adding Centessa's pipeline of orexin receptor 2 (OX2R) agonists including cleminorexton. The deal received court approval from the High Court of Justice of England and Wales and was completed on June 24-25, 2026.
• Orna TherapeuticsflagshipStrategic or Co-development Partner · 9 February 2026Definitive agreement to acquire Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo, for up to $2.4 billion in cash including upfront and milestone payments. Aims to develop in vivo cell therapies for autoimmune diseases and advances Lilly's position in genetic medicine and cell engineering technologies through Orna's engineered circular RNA (oRNA) platform.
• Ventyx Biosciences, Inc.coreStrategic or Co-development Partner · 6 February 2026Proposed acquisition under investigation by Kahn Swick & Foti, LLC; shareholders would receive $14.00 per share in cash. Investigation to determine whether consideration and process are adequate for Ventyx shareholders.
• Adverum BiotechnologiescoreStrategic or Co-development Partner · 24 October 2025Acquisition for up to $12.47 per share as part of Eli Lilly's ongoing growth and strategic expansion in biotherapeutics.
• NVIDIA CorporationflagshipTechnology or Integration · 18 June 2025Partnership to build an AI supercomputer for drug discovery designed to reduce the typical 3-6 year discovery phase by 1-2 years. Lilly is also integrating NVIDIA's BioNeMo Agent Toolkit for life sciences workflows including virtual screening, genomic analysis, and protein design. Positions Lilly's AI stack as a performance-first infrastructure choice.
• Verve TherapeuticsflagshipStrategic or Co-development Partner · 18 June 2025Acquisition for $1.3 billion, approximately 113% above recent trading average, to expand into cardiovascular genetic medicine and leverage Verve's CRISPR-based gene editing technology. Verve announced dosing of the first patient with its CRISPR-based technology aimed at treating genetic diseases.
• SiteOne TherapeuticscoreStrategic or Co-development Partner · 27 May 2025Acquisition of biotech firm developing small molecule inhibitors for pain and sensory hyperexcitability disorders for up to $1 billion. Includes Phase 2 candidate STC-004, researched as a non-opioid pain treatment, enhancing Lilly's efforts to develop addiction-free pain therapies.
• Morphic Holding, Inc.flagshipStrategic or Co-development Partner · 16 August 2024Completed acquisition via tender offer at $57 per share (approximately 92.8% of Morphic's shares), with Morphic subsequently delisted from Nasdaq. Morphic develops oral integrin therapies for serious chronic diseases including inflammatory bowel disease (IBD), expanding Lilly's gastroenterology pipeline and enabling potential combination treatments.
• Mablink BiosciencecoreStrategic or Co-development Partner · 19 October 2023Acquisition agreement reflecting the value of Mablink's pipeline and proprietary technology for drug conjugates. Transaction awaited approval from the French Ministry of the Economy.
• Sigilon Therapeutics, Inc.coreStrategic or Co-development Partner · 11 August 2023Acquisition completed via tender offer and merger, with cash plus contingent value rights. Aims to advance encapsulated cell therapies for type 1 diabetes. Total deal value up to approximately $309.6 million ($14.92 per share plus up to $111.64 CVR per share).
• Emergence TherapeuticscoreStrategic or Co-development Partner · 30 June 2023Acquisition of European ADC (antibody-drug conjugate) company completed in August 2023 for nearly half a billion dollars. Expands Lilly's portfolio in oncology and biotherapeutics.
• Akouos, Inc.flagshipStrategic or Co-development Partner · 18 October 2022Acquisition for approximately $487 million with a contingent value right that could increase the total payment up to $610 million, aimed at developing gene therapies for hearing loss. Akouos develops gene therapies for hereditary hearing loss, specifically otoferlin deficiency. AK-OTOF gene therapy restored hearing of a child within 30 days in a Phase 1/2 study.
• Protomer TechnologiescoreStrategic or Co-development Partner · 14 July 2021Acquisition of biotech firm specializing in peptide and protein engineering for over $1 billion. Aims to advance Lilly's diabetes therapies with Protomer's glucose-responsive insulin technology, including ongoing support for Protomer's development of next-generation protein therapeutics.
• Walmart PharmacyflagshipChannel Partner/ Reseller/ DistributorFull-service pharmacy partner offering in-store prescription pickup at over 4,600 Walmart locations nationwide for eligible LillyDirect medicines. Pricing is set by Lilly and consistent across all participating pharmacies.
• Amazon PharmacyflagshipChannel Partner/ Reseller/ DistributorFull-service digital first pharmacy offering wide selection, 24/7 U.S.-licensed pharmacist support, and free shipping to all 50 U.S. states in 1-4 days with same-day delivery in select metros. Most insurance plans accepted including Medicare and Medicaid.
• GifthealthcoreChannel Partner/ Reseller/ DistributorThird-party self-pay pharmacy fulfillment provider offering discreet home delivery or retail pickup. Customers who select this option agree not to seek insurance reimbursement.
• Prescryptive HealthcoreChannel Partner/ Reseller/ DistributorThird-party healthcare technology company providing digital control over prescriptions, medication cost transparency, and ways to pay less for Lilly medicines through LillyDirect.
• Fuze HealthcoreChannel Partner/ Reseller/ DistributorMail-order pharmacy dispensing services including online ordering, insurance and manufacturer savings processing, order notifications, refill reminders, and prescription renewals. Owns and operates mail-order pharmacies accepting most insurance plans.
• HealthTapcoreChannel Partner/ Reseller/ DistributorIndependent telehealth partner providing diabetes care through board-certified primary care physicians; $129 per visit with annual subscription, copay $0-30 with insurance; 7 days/week appointments, 24/7 messaging, within-24-hour wait times.
• WeightWatchers (WW Clinic)flagshipChannel Partner/ Reseller/ DistributorIndependent virtual care option for comprehensive obesity management. $74/month self-pay with access to clinical care, personalized nutrition plan, on-demand strength training videos, registered dietitians, and expert coaches. Clinician availability Monday-Friday with 24/7 messaging.
• Form HealthcoreChannel Partner/ Reseller/ DistributorIndependent virtual care option for obesity management offering $299/month membership or $10-100 insurance copay; nutrition counseling from registered dietitians with CBT approach; 5-10 day wait time; Monday-Friday clinician availability.
• SynapticurecoreChannel Partner/ Reseller/ DistributorIndependent nationwide virtual care for memory and thinking issues, offering neurologist support, care coordination, and access to clinical trials; access within two weeks plus 24/7 support line.
• Isaac HealthcoreChannel Partner/ Reseller/ DistributorIndependent nationwide virtual memory clinic for brain health and cognitive conditions, providing early detection, assessment, and care management to improve access and timely intervention.
• Neura HealthcoreChannel Partner/ Reseller/ DistributorIndependent telehealth for migraine with board-certified neurologists and headache specialists offering quick, convenient, and personalized care; some insurance plans accepted; specialists available in all 50 states and Washington D.C.
• Ognomy SleepcoreChannel Partner/ Reseller/ DistributorIndependent virtual care provider offering personalized sleep apnea care with at-home testing, most major insurance plans accepted including Medicare, first appointment within a week on average, and unlimited follow-ups and messaging.
• SesamecoreChannel Partner/ Reseller/ DistributorIndependent telehealth partner offering Type 2 diabetes support with $50-100/visit self-pay; integrates with trusted nutrition and mental health providers for holistic treatment plans.

Scale indicators15 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Novo Nordisk: Direct peer in GLP-1 obesity/diabetes with Wegovy and Ozempic. Holds ~15% of GLP-1 market vs. Lilly's ~65% and is the only other major tirzepatide-class competitor, making it the most directly comparable company on revenue mix, growth trajectory, and pipeline.

Broad incumbents

• Pfizer: Large incumbent pharma with broad therapeutic portfolio, oncology franchise, and an active oral GLP-1 (danuglipron) program. Competes with Lilly across diabetes, oncology, and vaccine adjacencies, and is mentioned alongside Lilly in the Section 301 Germany pricing probe context.
• Merck & Co. Major incumbent pharma with leading oncology (Keytruda), vaccines, and animal health franchises. Comparable as a large-cap R&D-intensive pharma facing patent cliffs and competing with Lilly in oncology and immunology.
• Roche: Global pharma incumbent with leading oncology, diagnostics, and immunology franchises. Comparable as a Swiss-based, R&D-heavy pharma competing with Lilly in oncology (Verzenio vs. Roche's breast cancer portfolio) and neuroscience.
• Novartis: Global pharma incumbent with strong oncology (Pluvicto, Kisqali), cardiovascular, and immunology franchises. Comparable in cardiometabolic disease and gene therapy through its BioArctic BrainTransporter collaboration, directly adjacent to Lilly's BioArctic partnership.
• Bristol-Myers Squibb: Major incumbent pharma with oncology (Opdivo, Yervoy), immunology, and cardiovascular franchises. Comparable as a large-cap pharma with M&A history and BioArctic BrainTransporter collaboration partner, overlapping with Lilly in neuroscience and oncology.
• AstraZeneca: Global pharma incumbent with leading oncology, cardiovascular (Farxiga for diabetes/heart failure), and rare disease franchises. Comparable in oncology and cardiometabolic disease, with Farxiga competing against Lilly's GLP-1/incretin franchise.
• Sanofi: Global pharma incumbent with leading immunology (Dupixent), vaccines, and diabetes (Lantus, Toujeo) franchises. Comparable as a large-cap pharma with diabetes/immunology overlap and active in rare disease, competing in similar therapeutic categories.
• AbbVie: Major incumbent pharma with leading immunology (Humira/Skyrizi/Rinvoq), oncology, and neuroscience franchises. Comparable in immunology (Lilly's Ebglyss, Omvoh vs. AbbVie's Skyrizi/Rinvoq) and as a patent-cliff-management reference case.
• Amgen: Large-cap biotech incumbent with leading oncology, cardiovascular (Repatha), and inflammation (Tezspire) franchises. Comparable as a major US-based R&D-heavy biotech/pharma with biologics manufacturing scale and competing in cardiometabolic and inflammation categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EliLillyandCo
• Facebookfacebook.com/elilillyandco
• LinkedInlinkedin.com/company/eli-lilly-and-company

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries11 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A55 records

Investments159 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eli Lilly